Top Markets
#1 Derive Derive +30.84%
#2 Cross Cross +17.10%
#3 Audiera Audiera +15.13%
#4 Humanity Humanity +10.96%
#5 Cap Cap +10.49%
#6 Velvet Velvet +10.37%
#7 The Bitcoin Bull The Bitcoin Bull +10.22%
#8 Geodnet Geodnet +8.81%
#9 Based Based +8.66%
#10 Biconomy Biconomy +7.67%
Coin of the day
Derive Derive
설정
언어
한국어
통화
USD
테마
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
주식 순위 #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
주가
$1.84
마지막 동기화: 2026-08-11
시가총액
$3.51M
변동 (1일)
0.46%
변동 (1년)
-62.71%
국가
US
거래 Dogwood Therapeutics, Inc. (DWTX)

카테고리

Healthcare
Dogwood Therapeutics, Inc. (DWTX)의 수익
2026 기준 수익 TTM: 0
Dogwood Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Dogwood Therapeutics, Inc.의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE